Half of HIV patients choose alternative medicine

June 19, 2003

UCLA and RAND researchers found that half of HIV-infected Americans use alternative medicine to supplement or replace antiretroviral drugs. One-quarter of HIV-positive patients choose alternative medicine that could interact with conventional therapy, yet do not inform their physicians. Reported in the June 19 edition of the Journal of AIDS, the findings emphasize the need for doctors to openly discuss alternative medicine practices with their patients.

Release URL, if available: The URL must point to the specific release, not a general page of releases or your organization's main homepage. "Antiretroviral drugs can help people with AIDS enjoy longer and healthier lives, but these medicines are expensive, can be hard to take and some may cause serious side effects," said Dr. An-Fu Hsiao, an internist and health services researcher at the David Geffen School of Medicine at UCLA

"Alternative medicine can ease antiretroviral drugs' side effects, but also create its own set of problems," he said. "Our findings illustrate why it's essential for doctors to discuss alternative medicine use with their patients."

The UCLA/RAND team reviewed data collected in person and by phone from a follow-up survey of 2,466 HIV-positive adults who participated in the HIV Cost and Services Utilization Study (HCSUS). This study surveyed a nationally representative group of 2,864 patients who received care for HIV disease at a U.S. inpatient or outpatient facility in 1996.

The HCSUS study asked participants (1) whether they used alternative medicine, (2) if they used it instead of or in addition to antiretroviral drug therapy and (3) whether they had discussed their alternative medicine use with their doctor.

Hsiao's team concentrated on forms of alternative medicine with the potential for harmful results. These methods included megavitamin doses, homeopathy and the unlicensed use of prescription drugs not designed to treat AIDS.

The UCLA/RAND team also focused on herbal medicine, which can react harmfully with antiretroviral drugs.

"Many HIV patients don't realize that the herb St. John's wort reduces the level of the antiretroviral drug Indinivar," Hsiao said. "This could result in therapeutic failure and the development of drug resistance."

Antiretroviral drugs and some methods of alternative medicine can produce similar side effects, so patients taking both therapies often wrongly blame the side effects on the drugs. If patients do not tell their doctor that they are using a form of alternative medicine, the physician may unnecessarily alter the patients' drug regimen. This also increases the patients' risk of treatment failure and drug resistance.

The UCLA/RAND study discovered the following:
"This is a wake-up call for physicians to ask their patients about alternative medicine use," Hsiao said. "Twenty-six percent of these HIV patients used a form of alternative medicine that could adversely interact with conventional treatment. Yet one-third of their doctors had no idea."

"Physicians can't predict which patients will use alternative medicine," he said. "Doctors need to learn to bring up the subject and to listen to their patients in a nonjudgmental manner."

Hsiao's co-authors included Dr. Martin Shapiro, Dr. Neil Wenger, Dr. Mitchell Wong, Dr. Honghu Liu and Dr. Ronald Anderson from UCLA; Dr. David Kanouse and Dr. Rebecca Collins from RAND, Santa Monica; Dr. Allen McCutchan from UCSD; and Dr. Allen Gifford and Dr. Sam Bozzette from the San Diego Veterans Affairs Healthcare System and RAND.
Major funding for HCSUS was provided by the federal Agency for Healthcare Research and Quality. The study also was supported by the U.S. Department of Health and Human Services, and by other organizations. The study was conducted by RAND in conjunction with a consortium of private and public research institutions.

University of California - Los Angeles

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.